Xolair denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Xolair (omalizumab) as Not Medically Necessary

UnitedHealthcare's medical-necessity denials for Xolair (omalizumab) typically reflect a determination that the submitted documentation does not satisfy the clinical criteria in UHC's published Xolair coverage policy. For Xolair's approved indications — which include allergic asthma, chronic idiopathic urticaria (CIU/CSU), nasal polyps, and food allergy (per current FDA label) — UHC's criteria commonly require documented evidence of disease severity, confirmation of an allergic or IgE-mediated basis for the condition, and prior treatment failure with required lower-step therapies. A denial is often administrative: the right information exists in the chart but was not included in the initial authorization request.

These denials are frequently overturned on appeal when a complete, organized record is submitted with the prescriber's individualized medical-necessity letter.

## Your Appeal Rights

• Internal appeal (ERISA §503): File a written internal appeal within the plan's deadline (typically 180 days from the denial). Include all documentation missing from the original PA request.
• External review (ACA §2719): If denied internally, independent external review is available within the four-month window from the final internal denial. The external reviewer's decision is binding on UHC.
• Expedited review: Request expedited processing if the patient has uncontrolled allergic asthma, active urticaria, or another condition where delay would cause meaningful harm.
• Peer-to-peer review: The prescriber may request a peer-to-peer call with UHC's reviewing medical director before or alongside the formal appeal.

## Documentation to Gather

1. Diagnosis confirmation — chart notes, allergy testing results, pulmonary function testing (for asthma), or relevant diagnostic workup confirming the specific FDA-approved indication. 2. Disease severity documentation — clinical notes, validated severity assessment tools, emergency visits, hospitalizations, or oral corticosteroid use history that demonstrates inadequate disease control. 3. Prior-treatment history with dates and outcomes — a dated list of every prior therapy tried, duration, and specific reason for discontinuation or failure. 4. Prescriber medical-necessity letter — individualized, signed, referencing UHC's coverage criteria and mapping each to specific patient chart facts. Should reference the applicable professional society guideline (e.g., NAEPP, AAAAI, or EAACI by organization name). 5. FDA prescribing label — confirm the approved indication and attach. 6. UHC coverage policy — request and attach the current policy; address each listed criterion explicitly.

## Criteria-Mapping Structure

| UHC Medical-Necessity Criterion | Supporting Chart Documentation | |---|---| | Confirmed diagnosis with appropriate workup | Diagnostic test results + chart notes | | Adequate trial of required prior therapies | Dated prior-treatment list + pharmacy records | | Disease severity meets policy threshold | Clinical notes, validated scores, hospitalization history | | Prescriber attestation | Attached individualized medical-necessity letter |

Organize the appeal so the criteria-mapping table appears first, with supporting documents tabbed behind it in the same order — this structure is most legible to an insurance medical reviewer.